BioWorld

Feb. 13, 2006

Acorda’s Second Attempt At IPO Successful: $33M

Acorda Therapeutics Inc. priced a $33 million initial public offering Friday, selling 5.5 million common shares at $6 apiece. (BioWorld Today) Read More

Private Placement Adding $27M To VaxGen’s Anthrax Drug Work

Deal Terms Reward Products: No Surprise From 2005 Trends

Black Box Warning Labels To Remain On All NSAIDs

After First Product Approval, BioMimetic Seeks $50M IPO

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 21, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...